The present embodiments relate generally to medical devices, and more particularly, to medical scopes for delivering therapeutic agents to a target site.
There are several instances in which it may become desirable to introduce therapeutic agents into the human or animal body. For example, therapeutic drugs or bioactive materials may be introduced to achieve a biological effect. The biological effect may include an array of targeted results, such as inducing hemostasis, sealing perforations, reducing restenosis likelihood, or treating cancerous tumors or other diseases.
Many of such therapeutic agents are injected using an intravenous (IV) technique and via oral medicine. While such techniques permit the general introduction of medicine, in many instances it may be desirable to provide localized or targeted delivery of therapeutic agents, which may allow for the guided and precise delivery of agents to selected target sites. For example, localized delivery of therapeutic agents to a tumor may reduce the exposure of the therapeutic agents to normal, healthy tissues, which may reduce potentially harmful side effects.
Localized delivery of therapeutic agents has been performed using catheters and similar introducer devices. By way of example, a catheter may be advanced towards a target site within the patient, then the therapeutic agent may be injected through a lumen of the catheter to the target site. Typically, a syringe or similar device may be used to inject the therapeutic agent into the lumen of the catheter. However, such a delivery technique may result in a relatively weak stream of the injected therapeutic agent.
Moreover, it may be difficult or impossible to deliver therapeutic agents in a targeted manner in certain forms, such as a powder form, to a desired site. For example, if a therapeutic powder is held within a syringe or other container, it may not be easily delivered through a catheter to a target site in a localized manner that may also reduce potentially harmful side effects.
Still further, some therapeutic agents are delivered using a catheter advanced through a lumen of a separate medical scope that enables imaging of the target site, such as an endoscope. However, using a separate catheter and medical scope may encompass limitations such as instrument sizes that can fit through the lumen of the scope, transportation of a patient to a specific suite capable of accommodating an endoscopic procedure, and the like.
The present embodiments provide systems and methods suitable for delivering a therapeutic agent to a target site. In one example, the system comprises a container for holding the therapeutic agent, and a pressure source having pressurized fluid, wherein the pressure source is in selective fluid communication with at least a portion of the container. A catheter is placed in fluid communication with the container, and has a lumen sized for delivery of the therapeutic agent to a target site. A housing is configured to securely retain the container. The system further comprises a camera having a camera head coupled to the catheter, wherein the camera provides a visual image of the target site during delivery of the therapeutic agent
In one embodiment, the system comprises a catheter adapter having a main body, a proximal end, and a distal end, wherein the catheter adapter is secured relative to the housing, and the distal end of the catheter adapter is coupled to a proximal end of the catheter. The proximal end of the catheter adapter comprises a first diameter and the distal end of the catheter adapter comprises a second diameter, wherein the first diameter is greater than the second diameter.
In one embodiment, the system comprises a valve assembly having an inlet port and at least first and second outlet ports. Pressurized fluid enters through the inlet port, and in a first state the pressurized fluid is directed through the first outlet port to provide insufflation with the absence of delivery of the therapeutic agent. In a second state, the pressurized fluid is directed through the second outlet port and into the container holding the therapeutic agent to provide delivery of the therapeutic agent.
In one embodiment, a method for delivering a therapeutic agent to a target site comprises actuating a pressure source having pressurized fluid, the pressure source in selective fluid communication with at least a portion of a container that holds a therapeutic agent, wherein a housing is configured to securely retain the container. 7The therapeutic agent is delivered, via the pressurized fluid, through a catheter in fluid communication with the container and a target site. The method further comprises visualizing the target site during delivery of the therapeutic agent using a camera having a camera head coupled to the catheter.
Other systems, methods, features and advantages of the invention will be, or will become, apparent to one with skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be within the scope of the invention, and be encompassed by the following claims.
The invention can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention. Moreover, in the figures, like referenced numerals designate corresponding parts throughout the different views.
In the present application, the term “proximal” refers to a direction that is generally towards a physician during a medical procedure, while the term “distal” refers to a direction that is generally towards a target site within a patient's anatomy during a medical procedure.
Referring now to
The system 20 further comprises a housing 22, which is suitable for securely holding, engaging and/or covering the container 30, pressure source 68, catheter 90, and other components described below. Preferably, the housing 22 comprises an upright section 24 that may be grasped by a user and a section 25 for engaging the container 30. An actuator 26 may be engaged by a user and selectively operated to perform the functions described below.
The container 30 may comprise any suitable size and shape for holding the therapeutic agent 38. In
The container 30 may further comprise an inlet tube 40, an outlet tube 50, and a cap 60, wherein the cap 60 is configured to be secured to the first region 31 of the container 30, as best seen in
During operation, fluid passed through the inlet port 62 of the cap 60 is directed through the inlet tube 40 and into the reservoir 33. Notably, the u-shaped curvature near the second region 32 of the container 30 effectively changes the direction of the fluid flow by approximately 180 degrees, such that the fluid originally flows in a direction from the first region 31 of the container 30 towards the second region 32, and then from the second region 32 back towards the first region 31. In the embodiment of
The second end 52 of the outlet tube 50 may terminate a predetermined distance above the second region 32 of the container 20, as shown in
Moreover, in some embodiments, a platform may be positioned within the container 30 above a curved portion associated with the second region 32, where the platform forms a substantially fluid tight seal with an inner surface of the container 30, thereby preventing the therapeutic agent 38 that is disposed in the reservoir 33 from reaching the curve at the second region 32, as explained further in U.S. Pat. No. 8,118,777. In such embodiment, the platform may comprise an opening though which fluid from the pressure source 68 is directed via a u-shaped tube disposed at the second region 32, as explained further in the '777 patent.
The cap 60 may comprise any suitable configuration for sealingly engaging the first region 31 of the container 30. In one example, an O-ring is held in place around a circumference of the cap 60 to hold the therapeutic agent 38 within the reservoir 33. The inlet and outlet tubes 40 and 50 may be held in place within the container 30 by one or more support members, such as those explained further in U.S. Pat. No. 8,118,777.
Further, as depicted in
Advantageously, in this manner, a first container holding a first therapeutic agent may be coupled to the housing 22 for use with the system 20, and subsequently a second container holding a second composition or agent may be coupled to the housing 22 for use with the system 20. By way of example, and without limitation, in one embodiment the system 20 may be “preloaded” with a first container 30 holding a therapeutic agent in the form of a hemostatic power. At a later time, it may be deemed beneficial to deliver a mucoadhesive composition, in which case the first container 30 may be rotated to disengage its flange 60a from the section 25 of the housing, and then insert a second container 30 into the section 25 of the housing 22 for delivery of the mucoadhesive composition. For the sake of brevity, the formulation in the container 30 will be referred to as a “therapeutic agent 38,” although as explained herein certain formulations in a container coupled to the housing 22 may be interchanged or varied and may or may not achieve a therapeutic effect per se.
The pressure source 68 may comprise one or more components capable of producing or furnishing a fluid having a desired pressure. In one embodiment, the pressure source 68 may comprise a pressurized fluid, such as a liquid or gas. For example, as shown in
The fluid may flow from the pressure source 68 through a pressure regulator, such as regulator valve 70 having a pressure outlet 72, as depicted in
Referring to
Various inlet and outlet ports are associated with the actuation valve assembly 80. In one embodiment, an inlet port 92, and three different outlet ports 93-95, are associated with the actuation valve assembly 80.
The inlet port 92 of the actuation valve assembly 80 may be coupled to the tubing 75 extending from the pressure outlet 72 of the regulator valve 70, as depicted in
In one embodiment, the piston 82 comprises a generally tubular body 83 having a lumen 84 extending between the proximal and distal regions 82a and 82b, as best seen in
The first slot 85 of the piston 82 is axially aligned with the inlet port 92 in at least one operational state. The second slot 86 of the piston 82 may be axially aligned with the outlet port 93 in a first state, and further may be axially aligned with the outlet port 94 in a second state, to thereby selectively provide fluid communication between the piston 82 and either the outlet port 93 or the outlet port 94, as explained further below.
When the actuation button 88 is not engaged by a user, the force provided by the compression spring 87 biases the piston 82 to the first state in which the first slot 85 of the piston 82 is axially aligned with the inlet port 92, and further in which the second slot 86 of the piston is axially aligned with the outlet port 93, as depicted in
When the actuation button 88 is depressed by the user in a manner to overcome the force provided by the compression spring 87, the piston 82 is advanced distally to the second state in which the first slot 85 of the piston 82 remains axially aligned with the inlet port 92, while the second slot 86 of the piston 82 becomes axially aligned with the outlet port 94. In this manner, pressurized fluid from the pressure source 68 (as regulated by the regulator valve 70) is directed into the outlet port 94 and into tubing 61, where it is then directed into the inlet port 62 of the cap 60 and into the container 30 holding the therapeutic agent 38. Notably, one or more sealing members, such as O-rings 96a-96c, may be used to provide a fluid tight seal as the pressurized fluid traverses through the housing 81.
In one embodiment, the first slot 85 comprises a length L1, and the second slot 86 comprises a length L2, where the length L1 is greater than the length L2, as depicted in
The distal region 82b of the piston 82 may be secured to the proximal end of the compression spring 87, as depicted in
The lumen 84 of the piston 82 is further in fluid communication with the outlet port 95 of the actuation valve assembly 80, such that pressurized fluid from the pressure source 68 is also delivered through the outlet port 95. In particular, a certain amount of pressurized fluid that enters through inlet port 92 flows distally beyond the first and second slots 85 and 86 in the piston 82, and through the distal region 82b of the piston 82, at which point the pressurized fluid then passes through a space in the interior of the compression spring 87, within the flange 89 that constrains the compression spring 87, and then into a lumen 97 distal to the flange 89, as shown in
The fluid reservoir 110 may comprise an irrigation fluid disposed in an interior of a container 118. Pressurized fluid traveling from the outlet port 95 and through the tubing 111 may pass through a valve 112 (when in an open state), then through an inlet port 113 associated with the container 118, as best seen in
Notably, the valve 112 is operable by a user to selectively inhibit flow of the pressurized fluid into the fluid reservoir 110, and consequently this action selectively stops or resumes delivery of the irrigation fluid to the target site. In one embodiment, the irrigation fluid in the fluid reservoir 110 may comprise water or another suitable fluid, which may be used to clean a camera lens associated with the system 20, as explained further below.
Although exemplary ports 92-95 and associated tubing (such as tubing 75, 101, 61 and 111) are depicted in
Referring now to
The catheter adapter 120 comprises a main body 121 having a proximal end 122 and a distal end 123, where the proximal end 122 comprises a diameter D1 that is greater than a diameter D2 at the distal end 123. At least one taper may be disposed between the proximal and distal ends 122 and 123 to transition from the larger diameter D1 to the smaller diameter D2. In the embodiment of
Advantageously, the larger diameter D1 at the proximal end 122 allows for receipt of extensive amounts of tubing and other components, as described herein, while the tapers then facilitate the transition to the smaller diameter D2, which is closer to the diameter of the catheter 90.
In
The tapering of the main body 121 of the catheter adapter 120 accommodates a reduction in the diameter of various lumens by a certain amount, when comparing larger inner diameters of the lumens 131-140 at the proximal end 122 of the catheter adapter 120 with smaller inner diameters of the corresponding lumens of the catheter 90. For example, in one embodiment, the therapeutic agent lumen 131 may comprise a first inner diameter at the proximal end 122 of the catheter adapter 120, and a second, smaller inner diameter in lumen 131a of the catheter 90, where the transition in inner diameters occurs along the catheter adapter 120, as depicted in
The reduction in inner diameter for the various lumens 131-140 is preferably at least 5% for one or more lumens, and in some embodiments between 10-90% for a given lumen, depending on the lumen and its purpose. It may be clinically important that certain lumens, such as the therapeutic agent lumen 131, do not become reduced too greatly from the first diameter at the proximal end 122 of the catheter adapter 120 relative to its corresponding smaller lumen 131a in the catheter, because too small of a catheter lumen may cause clogging. However, other lumens 131a-140a of the catheter 90 may achieve a considerably smaller diameter if there are no significant drawbacks to a smaller lumen.
As seen in
Advantageously, in this manner, the therapeutic agent lumen 131 of the catheter adapter 120 and the corresponding lumen 131a of the catheter 90 provide the selective delivery of either the therapeutic agent 38 and pressurized fluid from the pressure source 68, or alternatively only the pressurized fluid from the pressure source 68, depending on whether the second slot 86 of the piston 82 is axially aligned with the outlet port 93 in the first state, or alternatively axially aligned with the outlet port 94 in the second state. This provides for a simple and efficient ability for a user to switch between a therapeutic agent delivery mode or alternatively an insufflation mode (that lacks delivery of the therapeutic agent).
As shown in
Advantageously, the aspiration lumen 132a can provide a suction ability at or near the distal end of the catheter 90 and the target site, which can enable continuous or intermittent suctioning of the pressurized fluid into the catheter 90. This may be beneficial to reduce excessive gas distension from the therapeutic agent delivery mechanism, and may maintain volume and pressure in vivo. Further, the suction ability from the aspiration source, delivered via the aspiration lumen 132a, is advantageous to facilitate clearing out excessive amounts of therapeutic agent 38 that have aerosolized to restore visibility to a user.
If an external pump is used, continuous infusion of propellant and aspiration may be performed. Such continuous infusion may include the benefit of reducing clogging of the pathway for the delivery of the therapeutic agent 38. Further, continuous aspiration may help maintain a steady insufflation volume within the patient, and can be used to aspirate blood from the target site.
Optionally, the system 20 may incorporate a valve (not shown) to close off the provision of aspiration to the aspiration lumen 132a, which will facilitate insufflation of the affected bodily region. Such valve may be useful in a system with a constant positive pressure, i.e., where there is a continuous delivery of the pressurized fluid 68 towards the target site, which may be beneficial to prevent backflow of fluid that could clog the therapeutic agent lumen 131a of the catheter 90. In such a constant positive pressure system, such a valve to selectively permit aspiration will help transition between a general suction mode when in an open position, or an insufflation mode when in a closed position.
Referring still to
Referring still to
The camera 150 has a portion that is held within a camera container 156 that is coupled to the housing 22 of the system. Referring briefly back to
In one embodiment, the camera 150 comprises a CMOS camera that facilitates a visual image of the target site T (depicted in
Referring to
In one embodiment, four different deflection wires 161-164 are disposed through respective deflection wire lumens 137a-140a of the catheter 90, as depicted in
In
As shown in
The first deflection actuator 171 is operably coupled to the first wire follower 181 such that when the first deflection actuator 171 is rotated in a particular circumferential direction, it achieves a corresponding circumferential rotation of the first wire follower 181. In one example, a torque shaft 175 extends laterally between the first deflection actuator 171 and the first wire follower 181, as shown in
Similarly, the second wire follower 182 may comprise a main body 182a, and further may comprise a third coupling region 163a to which a proximal end of the third deflection wire 163 can be secured. The second wire follower 182 further comprises a fourth coupling region 164a to which a proximal end of the fourth deflection wire 164 can be secured. In this example, the third coupling region 163a is disposed about 180 degrees apart on the main body 182a relative to the fourth coupling region 162b, as depicted in
The second deflection actuator 172 is operably coupled to the second wire follower 182 such that when the second deflection actuator 172 is rotated in a particular circumferential direction, it achieves a corresponding circumferential rotation of the second wire follower 182. In one example, the second deflection actuator 172 may be provided with a plurality of pin holes 176 formed in an inward surface 177, and the second wire follower 182 may be provided with a plurality of pin holes 186 on a surface 187 facing inward, as depicted in
In one example, rotation of the first deflection actuator 171 in a first direction causes a corresponding circumferential movement of the first wire follower 181, which may impart a tensile force upon the first deflection wire 161 to move the distal end 99 of the catheter 90 in an upward direction. Conversely, rotation of the first deflection actuator 171 in an opposing second direction causes circumferential movement of the first wire follower 181 in the second direction, which may impart a tensile force upon the second deflection wire 162 to move the distal end 99 of the catheter 90 in a downward direction.
Further, rotation of the second deflection actuator 172 in a first direction causes a corresponding circumferential movement of the second wire follower 182, which may impart a tensile force upon the third deflection wire 163 to move the distal end 99 of the catheter 90 in a left-to-right direction. Conversely, rotation of the second deflection actuator 172 in an opposing second direction causes circumferential movement of the second wire follower 182 in the second direction, which may impart a tensile force upon the fourth deflection wire 164 to move the distal end 99 of the catheter 90 in a right-to-left direction.
In this manner, the four deflection wires 161-164 can move the distal end 99 of the catheter 90 in four distinct directions, which will facilitate imaging at the target site T by the camera head 154.
Referring to
In the example of
In operation, the distal end 99 of the catheter 90 may be positioned in relatively close proximity to the target site. The catheter 90 may be advanced to the target site using an open technique, an intraluminal technique, through the mouth, colon, nostrils or using any other suitable technique, and the camera 150 may facilitate positioning at the target site.
When the catheter 90 is positioned at the desired target site, the pressure source 68 may be actuated by engaging the actuator 26. As noted above, the pressurized fluid may flow from the pressure source 68 through a regulator valve 70 and be brought to a desired pressure and rate. It will be appreciated that any passive flow regulator may be used to bring the pressurized fluid to the desired parameters. The fluid then flows through the tubing 75 and into the actuation valve assembly 80 via the inlet port 91.
The pressurized fluid then flows through the outlet ports 93 and 95 when the actuation button 88 is in its relaxed state. At this time, the user has the option to selectively provide insufflation fluid by actuating the valve 102 given the pressurized fluid is available through the outlet port 93.
When the user desires to deliver the therapeutic agent 38, the user depresses the actuation button, thereby overcoming the force from the compression spring 87 and aligning the second slot 86 of the plunger 82 with the outlet port 94. At this time, the regulated pressurized fluid flows through the outlet port 94 and through the tubing 61 towards the container 30. The fluid is then directed through the inlet port 62, through the inlet tube 40 within the container 30, and then the direction of pressurized fluid is redirected upward at the bottom of the container 30. Regulated fluid then urges the therapeutic agent 38 through the outlet tube 50. The fluid and the therapeutic agent 38 then exit through the first end 51 of the outlet tube 50, through the outlet port 63 of the cap 60, then thorough the coupler 65, the catheter adapter 120 and the ultimately through the catheter 90, as explained in detail above, thereby delivering the therapeutic agent 38 to the target site at a desired pressure.
The system 20 may be used to deliver the therapeutic agent 38 in a wide range of procedures and the therapeutic agent 38 may be chosen to perform a desired function upon ejection from the distal end of the catheter 90. Solely by way of example, and without limitation, the provision of the therapeutic agent 38 may be used for providing hemostasis, closing perforations, performing lithotripsy, treating tumors and cancers, treat renal dialysis fistulae stenosis, vascular graft stenosis, and the like. The therapeutic agent 38 can be delivered during procedures such as coronary artery angioplasty, renal artery angioplasty and carotid artery surgery, or may be used generally for treating various other cardiovascular, respiratory, gastroenterology or other conditions. The above-mentioned systems also may be used in transvaginal, umbilical, nasal, and bronchial/lung related applications.
For example, if used for purposes of hemostasis, thrombin, epinephrine, or a sclerosant may be provided to reduce localized bleeding. Similarly, if used for closing a perforation, a fibrin sealant may be delivered to a localized lesion. In addition to the hemostatic properties of the therapeutic agent 38, it should be noted that the relatively high pressure of the fluid and therapeutic agent, by itself, may act as a mechanical tamponade by providing a compressive force, thereby reducing the time needed to achieve hemostasis.
The therapeutic agent 38 may be selected to perform one or more desired biological functions, for example, promoting the ingrowth of tissue from the interior wall of a body vessel, or alternatively, to mitigate or prevent undesired conditions in the vessel wall, such as restenosis. Many other types of therapeutic agents 38 may be used in conjunction with the system 20.
The therapeutic agent 38 may be delivered in any suitable form. For example, the therapeutic agent 38 may comprise a powder, liquid, gel, aerosol, or other substance. Advantageously, the pressure source 68 may facilitate delivery of the therapeutic agent 38 in any one of these forms.
The therapeutic agent 38 employed also may comprise an antithrombogenic bioactive agent, e.g., any bioactive agent that inhibits or prevents thrombus formation within a body vessel. Types of antithrombotic bioactive agents include anticoagulants, antiplatelets, and fibrinolytics. Anticoagulants are bioactive materials that act on any of the factors, cofactors, activated factors, or activated cofactors in the biochemical cascade and inhibit the synthesis of fibrin. Antiplatelet bioactive agents inhibit the adhesion, activation, and aggregation of platelets, which are key components of thrombi and play an important role in thrombosis. Fibrinolytic bioactive agents enhance the fibrinolytic cascade or otherwise aid in dissolution of a thrombus. Examples of antithrombotics include but are not limited to anticoagulants such as thrombin, Factor Xa, Factor Vila and tissue factor inhibitors; antiplatelets such as glycoprotein IIb/IIIa, thromboxane A2, ADP-induced glycoprotein IIb/IIIa, and phosphodiesterase inhibitors; and fibrinolytics such as plasminogen activators, thrombin activatable fibrinolysis inhibitor (TAFI) inhibitors, and other enzymes which cleave fibrin.
Additionally, or alternatively, the therapeutic agent 38 may include thrombolytic agents used to dissolve blood clots that may adversely affect blood flow in body vessels. A thrombolytic agent is any therapeutic agent that either digests fibrin fibers directly or activates the natural mechanisms for doing so. Examples of commercial thrombolytics, with the corresponding active agent in parenthesis, include, but are not limited to, Abbokinase (urokinase), Abbokinase Open-Cath (urokinase), Activase (alteplase, recombinant), Eminase (anitstreplase), Retavase (reteplase, recombinant), and Streptase (streptokinase). Other commonly used names are anisoylated plasminogen-streptokinase activator complex; APSAC; tissue-type plasminogen activator (recombinant); t-PA; rt-PA. The therapeutic agent 38 may comprise coating-forming agents to protect or assist in healing of lesions and/or wounds.
However, while a few exemplary therapeutic agents 38 have been described, it will be apparent that numerous other suitable therapeutic agents may be used in conjunction with the system 20 and delivered through the catheter 90.
Advantageously, the system 20 permits localized delivery of a desired quantity of the therapeutic agent 38 at a desired, regulated pressure. Since the distal end of the catheter 90 may be placed in relatively close proximity to a target site, the system 20 provides significant advantages over therapeutic agents delivered orally or through an IV system and may reduce accumulation of the therapeutic agent 38 in healthy tissues, thereby reducing side effects. Moreover, the delivery of the therapeutic agent 38 to the target site is performed in a relatively fast manner due to the relatively high pressure of the fluid, thereby providing a prompt delivery to the target site compared to previous devices.
The therapeutic agent 38 may have a specific range of properties that make it suitable for delivery through the catheter 90. In particular, the mass of an individual particle of the therapeutic agent 38 should be within a specific range. If a particle of the therapeutic agent 38 is too heavy, it will require too much pressure to travel the length of the catheter 90 and can result in clogging of the catheter 90. If the particle is too light, it will aerosolize within the patient's body, e.g., in the gastrointestinal space, instead of being propelled to a target site. In addition to mass of an individual particle of the therapeutic agent 38, the size of the particle is important for ensuring proper delivery through the catheter 90. If the particle of the therapeutic agent 38 is too large in size, then it will be prone to clogging within the delivery catheter 90. If the particle is too small, it may have a higher likelihood of being aerosolized instead of being propelled to the target site. Details of suitable properties for the therapeutic agent 30 relative to the catheter 90, which are expected to reduce the likelihood of events such as aerosolization of the particles and clogging of the catheter, are described in U.S. Pat. No. 9,867,931, which is hereby incorporated by reference in its entirety.
Additional steps of operation of the system 20 have been described above. For example, the user may optionally apply suction via the aspiration lumen 132a, may selectively provide irrigation fluid via the irrigation lumen 133a (when the irrigation valve 112 is in an open position) to help clean the camera 150, and may engage the deflection actuators 171 and 172 to selectively maneuver the deflection wires 161-164, thereby moving the distal end of the catheter 90 in at least four distinct directions, as explained in detail above.
Advantageously, in the system 20, because a camera 150 is provided as part of the system, including a dedicated lumen in the catheter 90, a separate visualization system such as an endoscope is not required. In this manner, the system 20 can be used as a stand-alone therapeutic agent delivery system with its own imaging capabilities, and is not required to be delivered through a lumen of a separate scope, such as an endoscope.
As a related advantage, the system 20 therefore is not impacted by instrument sizes that can fit through the lumen of a conventional scope. Moreover, since the catheter 90 is not required to be delivered through a conventional scope, transportation of a patient to a specific suite capable of accommodating an endoscopic procedure may be avoided.
Referring now to
In the embodiment of
The system
Advantageously, the system of
Referring to
In the embodiment of
As seen in
In
Notably, in the embodiment of
In
Referring to
As best seen in
Referring still to
The third adapter 342, best seen in
In
In the embodiment of
Referring to
While various embodiments of the invention have been described, the invention is not to be restricted except in light of the attached claims and their equivalents. Moreover, the advantages described herein are not necessarily the only advantages of the invention and it is not necessarily expected that every embodiment of the invention will achieve all of the advantages described.
This invention claims the benefit of priority of U.S. Provisional Application Ser. No. 63/035,270, entitled “Medical Scopes for Delivering Therapeutic Agents,” filed Jun. 5, 2020, the disclosure of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
39678 | Russell | Aug 1863 | A |
170182 | Molesworth | Nov 1875 | A |
280202 | Mattson | Jun 1883 | A |
442785 | Schoettl | Dec 1890 | A |
460458 | Bates | Sep 1891 | A |
471865 | Howard | Mar 1892 | A |
533489 | Ogram | Feb 1895 | A |
566411 | Schoene | Aug 1896 | A |
576437 | Elliot | Feb 1897 | A |
693587 | Campbell | Feb 1902 | A |
775985 | McKain | Nov 1904 | A |
881238 | Hasbrouck | Mar 1908 | A |
904149 | Rachmann | Nov 1908 | A |
938648 | DeVilbiss | Nov 1909 | A |
1022601 | Rumberg et al. | Apr 1912 | A |
1114114 | Cochenour | Oct 1914 | A |
1145520 | Smith | Jul 1915 | A |
1261503 | Figgis | Apr 1918 | A |
1357452 | Hall | Nov 1920 | A |
1466119 | Claflin | Aug 1923 | A |
1521396 | Scott | Dec 1924 | A |
1685280 | Findley | Sep 1928 | A |
1934793 | Crain et al. | Nov 1933 | A |
2004402 | Conklin | Jun 1935 | A |
2151418 | Bolte | Mar 1939 | A |
2223611 | Gross | Dec 1940 | A |
2307986 | Bolte et al. | Jan 1943 | A |
2390313 | Macgill | Dec 1945 | A |
2507702 | Fields | May 1950 | A |
2519555 | Fields | Aug 1950 | A |
2609155 | Fosnaugh | Sep 1952 | A |
2632444 | Kas | Mar 1953 | A |
2805013 | Cordis | Sep 1957 | A |
2934314 | Chambers et al. | Apr 1960 | A |
2956579 | Moore et al. | Oct 1960 | A |
3016895 | Sein et al. | Jan 1962 | A |
3050261 | Littlefield | Aug 1962 | A |
3207618 | De Hart | Sep 1965 | A |
3506008 | Huck | Apr 1970 | A |
3540444 | Moreland | Nov 1970 | A |
3572335 | Robinson | Mar 1971 | A |
3589363 | Banko et al. | Jun 1971 | A |
3599866 | Bolton | Aug 1971 | A |
3632046 | Hengesbach | Jan 1972 | A |
3647143 | Gauthier et al. | Mar 1972 | A |
3649299 | Sholl | Mar 1972 | A |
3667465 | Voss | Jun 1972 | A |
3710400 | Sparks | Jan 1973 | A |
3742955 | Battista et al. | Jul 1973 | A |
3744493 | Booher et al. | Jul 1973 | A |
3762410 | Bindel | Oct 1973 | A |
3788315 | Laurens | Jan 1974 | A |
3815595 | Bar | Jun 1974 | A |
3900022 | Widran | Aug 1975 | A |
3916896 | Ballard | Nov 1975 | A |
4009637 | Bittner | Mar 1977 | A |
4017007 | Riccio | Apr 1977 | A |
4040420 | Speer | Aug 1977 | A |
4174811 | Binder et al. | Nov 1979 | A |
4184258 | Barrington et al. | Jan 1980 | A |
4204539 | Van Brugge | May 1980 | A |
4204645 | Hopp | May 1980 | A |
4210140 | James et al. | Jul 1980 | A |
4359049 | Redl et al. | Nov 1982 | A |
4391276 | Lazarus et al. | Jul 1983 | A |
4423727 | Widran et al. | Jan 1984 | A |
4427450 | Kostansek | Jan 1984 | A |
4427650 | Stroetmann | Jan 1984 | A |
4516442 | Davis | May 1985 | A |
4534345 | Wetterlin | Aug 1985 | A |
4539716 | Bell | Sep 1985 | A |
4552556 | Urquhart et al. | Nov 1985 | A |
4578067 | Cruz, Jr. | Mar 1986 | A |
4594987 | Wataya et al. | Jun 1986 | A |
4606501 | Bate et al. | Aug 1986 | A |
4620847 | Shishov et al. | Nov 1986 | A |
4631055 | Redl et al. | Dec 1986 | A |
4637816 | Mann | Jan 1987 | A |
H257 | Barditch et al. | Apr 1987 | H |
4655211 | Sakamoto et al. | Apr 1987 | A |
4657536 | Dorman | Apr 1987 | A |
4735616 | Eibl et al. | Apr 1988 | A |
4738658 | Magro et al. | Apr 1988 | A |
4738740 | Pinchuk | Apr 1988 | A |
4752466 | Saferstein et al. | Jun 1988 | A |
4790819 | Li et al. | Dec 1988 | A |
4798606 | Pinchuk | Jan 1989 | A |
4803977 | Kremer, Jr. | Feb 1989 | A |
4846405 | Zimmermann | Jul 1989 | A |
4850355 | Brooks et al. | Jul 1989 | A |
D303139 | Morgan | Aug 1989 | S |
4872450 | Austad | Oct 1989 | A |
4874368 | Miller et al. | Oct 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4900303 | Lemelson | Feb 1990 | A |
4902278 | Maget et al. | Feb 1990 | A |
4902281 | Avoy | Feb 1990 | A |
4927410 | Kovacs | May 1990 | A |
4929246 | Sinofsky | May 1990 | A |
4941874 | Sandow et al. | Jul 1990 | A |
4941880 | Burns | Jul 1990 | A |
4945050 | Sanford et al. | Jul 1990 | A |
4946870 | Partain, III et al. | Aug 1990 | A |
4950234 | Fujioka et al. | Aug 1990 | A |
4969874 | Michel et al. | Nov 1990 | A |
4978336 | Capozzi et al. | Dec 1990 | A |
4994028 | Leonard et al. | Feb 1991 | A |
5009637 | Newman et al. | Apr 1991 | A |
5015580 | Christou et al. | May 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5053000 | Booth et al. | Oct 1991 | A |
5059187 | Sperry et al. | Oct 1991 | A |
5061180 | Wiele | Oct 1991 | A |
5063025 | Ito | Nov 1991 | A |
5064413 | McKinnon et al. | Nov 1991 | A |
5106370 | Stewart | Apr 1992 | A |
5116315 | Capozzi et al. | May 1992 | A |
5120657 | McCabe et al. | Jun 1992 | A |
5129825 | Discko, Jr. | Jul 1992 | A |
5129882 | Weldon et al. | Jul 1992 | A |
5133701 | Han | Jul 1992 | A |
5135484 | Wright | Aug 1992 | A |
5141515 | Eberbach | Aug 1992 | A |
5147292 | Kullas et al. | Sep 1992 | A |
5149655 | McCabe et al. | Sep 1992 | A |
5165604 | Copp, Jr. | Nov 1992 | A |
5176642 | Clement | Jan 1993 | A |
5179022 | Sanford et al. | Jan 1993 | A |
D333000 | Good et al. | Feb 1993 | S |
5204253 | Sanford et al. | Apr 1993 | A |
5207641 | Allton | May 1993 | A |
5219328 | Morse et al. | Jun 1993 | A |
5226567 | Sansalone | Jul 1993 | A |
5226877 | Epstein | Jul 1993 | A |
RE34365 | Theeuwes | Aug 1993 | E |
5273531 | Knoepfler | Dec 1993 | A |
5292309 | Van Tassel et al. | Mar 1994 | A |
5310407 | Casale | May 1994 | A |
5312331 | Knoepfler | May 1994 | A |
5312333 | Churinetz et al. | May 1994 | A |
5328459 | Laghi | Jul 1994 | A |
5330426 | Kriesel et al. | Jul 1994 | A |
5337740 | Armstrong et al. | Aug 1994 | A |
5391183 | Janzen et al. | Feb 1995 | A |
5392992 | Farnsteiner et al. | Feb 1995 | A |
5395326 | Haber et al. | Mar 1995 | A |
5405607 | Epstein | Apr 1995 | A |
5415631 | Churinetz et al. | May 1995 | A |
5429278 | Sansalore | Jul 1995 | A |
5445512 | Terakura et al. | Aug 1995 | A |
5445612 | Terakura et al. | Aug 1995 | A |
5447499 | Allaire et al. | Sep 1995 | A |
5469994 | Reh et al. | Nov 1995 | A |
5470311 | Setterstrom et al. | Nov 1995 | A |
5484403 | Yaokum et al. | Jan 1996 | A |
5497232 | Watano et al. | Mar 1996 | A |
5503623 | Tilton, Jr. | Apr 1996 | A |
5513630 | Century | May 1996 | A |
5518546 | Williams et al. | May 1996 | A |
5520658 | Holm | May 1996 | A |
5520667 | Roche | May 1996 | A |
5538162 | Reh et al. | Jul 1996 | A |
5546932 | Galli | Aug 1996 | A |
5553741 | Sancoff et al. | Sep 1996 | A |
5558646 | Roche | Sep 1996 | A |
5582596 | Fukunaga et al. | Dec 1996 | A |
5584807 | McCabe | Dec 1996 | A |
5584815 | Pawelka et al. | Dec 1996 | A |
5601603 | Illi | Feb 1997 | A |
5605541 | Holm | Feb 1997 | A |
5612050 | Rowe et al. | Mar 1997 | A |
5665067 | Linder et al. | Sep 1997 | A |
5697947 | Wolf et al. | Dec 1997 | A |
5707402 | Heim | Jan 1998 | A |
5749968 | Melanson et al. | May 1998 | A |
5759171 | Coelho | Jun 1998 | A |
5788625 | Plouhar et al. | Aug 1998 | A |
5865796 | McCabe | Feb 1999 | A |
5873530 | Chizinsky | Feb 1999 | A |
5882332 | Wijay | Mar 1999 | A |
5895400 | Abela | Apr 1999 | A |
5902228 | Schulsinger et al. | May 1999 | A |
5919184 | Tilton, Jr. | Jul 1999 | A |
5951531 | Ferdman et al. | Sep 1999 | A |
6007515 | Epstein et al. | Dec 1999 | A |
6013050 | Bellhouse et al. | Jan 2000 | A |
6021776 | Allred et al. | Feb 2000 | A |
6027471 | Fallon et al. | Feb 2000 | A |
6059749 | Marx | May 2000 | A |
6077217 | Love et al. | Jun 2000 | A |
6117150 | Pingleton et al. | Sep 2000 | A |
6123070 | Bruna | Sep 2000 | A |
6158624 | Grigg et al. | Dec 2000 | A |
6165201 | Sawhney et al. | Dec 2000 | A |
6368300 | Fallon et al. | Apr 2002 | B1 |
6394975 | Epstein | May 2002 | B1 |
6428505 | Taylor et al. | Aug 2002 | B1 |
6454786 | Holm et al. | Sep 2002 | B1 |
6461325 | Delmotte et al. | Oct 2002 | B1 |
6461361 | Epstein | Oct 2002 | B1 |
6478754 | Babeav | Nov 2002 | B1 |
6554792 | Hughes et al. | Apr 2003 | B2 |
6537246 | Unger et al. | May 2003 | B1 |
6610026 | Cragg et al. | Aug 2003 | B2 |
6616652 | Harper | Sep 2003 | B1 |
6641800 | Mistry et al. | Nov 2003 | B1 |
6689108 | Lavi et al. | Feb 2004 | B2 |
6716190 | Glines et al. | Apr 2004 | B1 |
6723067 | Nielson | Apr 2004 | B2 |
6811550 | Holland et al. | Nov 2004 | B2 |
6843388 | Hollars | Jan 2005 | B1 |
6863660 | Marx | Mar 2005 | B2 |
6905475 | Hauschild et al. | Jun 2005 | B2 |
6913596 | Davey | Jul 2005 | B2 |
6939324 | Gonnelli et al. | Sep 2005 | B2 |
7101862 | Chochrum et al. | Sep 2006 | B2 |
7156880 | Evans et al. | Jan 2007 | B2 |
7178744 | Tapphorn et al. | Feb 2007 | B2 |
7182748 | Potter et al. | Feb 2007 | B1 |
7291133 | Kindler et al. | Jun 2007 | B1 |
7334598 | Hollars | Feb 2008 | B1 |
7455248 | Kablik et al. | Nov 2008 | B2 |
7534449 | Saltzman et al. | May 2009 | B2 |
7544177 | Gertner | Jun 2009 | B2 |
7547292 | Sheldrake et al. | Jun 2009 | B2 |
7588171 | Reedy et al. | Sep 2009 | B2 |
7632245 | Cowan et al. | Dec 2009 | B1 |
7648083 | Hornsby et al. | Jan 2010 | B2 |
7673783 | Morgan et al. | Mar 2010 | B2 |
7691244 | Levitan et al. | Apr 2010 | B2 |
7744526 | McAlister et al. | Jun 2010 | B2 |
7776822 | Terman | Aug 2010 | B2 |
7824373 | Kim | Nov 2010 | B2 |
7857167 | Hollars | Dec 2010 | B1 |
7914517 | Baran et al. | Mar 2011 | B2 |
8083721 | Miller | Dec 2011 | B2 |
8109872 | Kennedy, II et al. | Feb 2012 | B2 |
8118772 | Ducharme | Feb 2012 | B2 |
8118777 | Ducharme et al. | Feb 2012 | B2 |
8210449 | Peterson et al. | Jul 2012 | B2 |
8235937 | Palasis et al. | Aug 2012 | B2 |
8292197 | Ballu et al. | Oct 2012 | B2 |
8298175 | Hirschel et al. | Oct 2012 | B2 |
RE43824 | Sheldrake et al. | Nov 2012 | E |
8361054 | Ducharme et al. | Jan 2013 | B2 |
8372092 | Gabel et al. | Feb 2013 | B2 |
8418775 | Blomet et al. | Apr 2013 | B2 |
8523821 | Miller | Sep 2013 | B2 |
8721582 | Ji | May 2014 | B2 |
8728032 | Ducharme et al. | May 2014 | B2 |
8827980 | Ji | Sep 2014 | B2 |
8944926 | Vogt et al. | Feb 2015 | B2 |
8950396 | Wachtel et al. | Feb 2015 | B2 |
9101744 | Ducharme | Aug 2015 | B2 |
9205207 | Ji | Dec 2015 | B2 |
9205240 | Greenhalgh et al. | Dec 2015 | B2 |
9375533 | Ducharme et al. | Jun 2016 | B2 |
9393583 | Tu | Jul 2016 | B2 |
9474915 | Gonzales et al. | Oct 2016 | B2 |
9486609 | Ross | Nov 2016 | B2 |
9555185 | Foster et al. | Jan 2017 | B2 |
9629966 | Ji | Apr 2017 | B2 |
9837931 | Luo | Dec 2017 | B2 |
9839772 | Ducharme | Dec 2017 | B2 |
9867931 | Gittard | Jan 2018 | B2 |
9895527 | Spohn et al. | Feb 2018 | B2 |
9907456 | Miyioshi | Mar 2018 | B2 |
10463811 | Lee et al. | Nov 2019 | B2 |
10542868 | Gordon et al. | Jan 2020 | B2 |
10610665 | Krueger et al. | Apr 2020 | B2 |
10806853 | Gittard | Oct 2020 | B2 |
10842368 | Nave | Nov 2020 | B2 |
10994110 | Ducharme | May 2021 | B2 |
11344314 | Tal et al. | May 2022 | B2 |
11766546 | Pic et al. | Sep 2023 | B2 |
20010056256 | Hughes et al. | Dec 2001 | A1 |
20020165483 | Miller | Nov 2002 | A1 |
20020169416 | Gonnelli | Nov 2002 | A1 |
20030023202 | Nielson et al. | Jan 2003 | A1 |
20030032862 | Ota et al. | Feb 2003 | A1 |
20030069549 | MacMahon | Apr 2003 | A1 |
20030108511 | Sawhney | Jun 2003 | A1 |
20030170250 | Ezrin et al. | Sep 2003 | A1 |
20030181917 | Gertner | Sep 2003 | A1 |
20030216695 | Yang | Nov 2003 | A1 |
20040059283 | Kirwan et al. | Mar 2004 | A1 |
20040073863 | Mousley | Apr 2004 | A1 |
20040215135 | Sheldrake et al. | Oct 2004 | A1 |
20040262340 | Kress | Dec 2004 | A1 |
20050070848 | Kim et al. | Mar 2005 | A1 |
20050125002 | Baran et al. | Jun 2005 | A1 |
20050205087 | Kablik et al. | Sep 2005 | A1 |
20060002852 | Saltzman et al. | Jan 2006 | A1 |
20060052295 | Terman | Mar 2006 | A1 |
20060100572 | DiMatteo et al. | May 2006 | A1 |
20060252993 | Freed | Nov 2006 | A1 |
20060028664 | McAllister et al. | Dec 2006 | A1 |
20070005002 | Millman | Jan 2007 | A1 |
20070088317 | Hyde | Apr 2007 | A1 |
20070199824 | Hoerr et al. | Aug 2007 | A1 |
20070240989 | Levitan et al. | Oct 2007 | A1 |
20070241119 | Durkin et al. | Oct 2007 | A1 |
20080021374 | Kawata | Jan 2008 | A1 |
20080027272 | Kadykowski | Jan 2008 | A1 |
20080120992 | Levy et al. | May 2008 | A1 |
20080132891 | Nobis et al. | Jun 2008 | A1 |
20080287911 | El-Nounou et al. | Nov 2008 | A1 |
20090000615 | Pohlmann | Jan 2009 | A1 |
20090007904 | Schuster et al. | Jan 2009 | A1 |
20090030274 | Goldfarb et al. | Jan 2009 | A1 |
20090071470 | Abrams | Mar 2009 | A1 |
20090145982 | Blomet et al. | Jun 2009 | A1 |
20090155342 | Diegelmann et al. | Jun 2009 | A1 |
20090234227 | Punga | Sep 2009 | A1 |
20090234374 | Gabel et al. | Sep 2009 | A1 |
20090234380 | Gabel et al. | Sep 2009 | A1 |
20090240197 | Cowan et al. | Sep 2009 | A1 |
20090248056 | Gabel et al. | Oct 2009 | A1 |
20090281486 | Ducharme | Nov 2009 | A1 |
20090326453 | Adams et al. | Dec 2009 | A1 |
20100101579 | Levy | Apr 2010 | A1 |
20100121261 | Kablik et al. | May 2010 | A1 |
20100137796 | Perry et al. | Jun 2010 | A1 |
20100160897 | Ducharme et al. | Jun 2010 | A1 |
20100191185 | Miller | Jul 2010 | A1 |
20100305505 | Ducharme et al. | Dec 2010 | A1 |
20110178495 | Ji | Jul 2011 | A1 |
20110272438 | Vogt et al. | Nov 2011 | A1 |
20120116296 | Ducharme et al. | May 2012 | A1 |
20120136301 | Miller | May 2012 | A1 |
20130046278 | Ji | Feb 2013 | A1 |
20130059113 | Hatton et al. | Mar 2013 | A1 |
20130100801 | Allan et al. | Apr 2013 | A1 |
20130104884 | Vazales et al. | May 2013 | A1 |
20130110080 | Ducharme | May 2013 | A1 |
20140200402 | Snoke | Jul 2014 | A1 |
20140207097 | Ji | Jul 2014 | A1 |
20140248437 | Schroeder et al. | Sep 2014 | A1 |
20140271491 | Gittard et al. | Sep 2014 | A1 |
20140296806 | Williams et al. | Oct 2014 | A1 |
20140346257 | Reetz, III et al. | Nov 2014 | A1 |
20150216516 | Steffen | Aug 2015 | A1 |
20150306317 | Ducharme et al. | Oct 2015 | A1 |
20170224762 | McIntosh et al. | Aug 2017 | A1 |
20170232141 | Surti et al. | Aug 2017 | A1 |
20170265879 | Washburn, II et al. | Sep 2017 | A1 |
20170296221 | DiCaprio et al. | Oct 2017 | A1 |
20180001067 | Christakis et al. | Jan 2018 | A1 |
20180056052 | Swanson et al. | Mar 2018 | A1 |
20180099088 | Gittard | Apr 2018 | A1 |
20180161526 | Canner et al. | Jun 2018 | A1 |
20180193011 | Keene et al. | Jul 2018 | A1 |
20180193574 | Smith et al. | Jul 2018 | A1 |
20180221296 | Holekamp et al. | Aug 2018 | A1 |
20180344659 | Holekamp et al. | Dec 2018 | A1 |
20190008601 | Pereira et al. | Jan 2019 | A1 |
20190232030 | Pic et al. | Aug 2019 | A1 |
20190308213 | Mispel-Beyer | Oct 2019 | A1 |
20190322442 | Thomsen | Oct 2019 | A1 |
20190343980 | Gittard et al. | Nov 2019 | A1 |
20190351207 | Quan et al. | Nov 2019 | A1 |
20190388665 | Christakis et al. | Dec 2019 | A1 |
20200046213 | Bendory et al. | Feb 2020 | A1 |
20200060536 | Rylander et al. | Feb 2020 | A1 |
20200061310 | Goodman et al. | Feb 2020 | A1 |
20200100986 | Pic et al. | Apr 2020 | A1 |
20200101476 | Pic et al. | Apr 2020 | A1 |
20200222218 | Poulsen et al. | Jul 2020 | A1 |
20200397983 | Gittard | Dec 2020 | A1 |
20210022761 | Looper et al. | Jan 2021 | A1 |
20210106717 | Carruthers et al. | Apr 2021 | A1 |
20210161515 | Pic et al. | Jun 2021 | A1 |
20210162122 | Pic et al. | Jun 2021 | A1 |
20210187190 | Congdon et al. | Jun 2021 | A1 |
20210228852 | Ducharme | Jul 2021 | A1 |
20210275760 | Hunter et al. | Sep 2021 | A1 |
20210299400 | Cauche et al. | Sep 2021 | A1 |
20210346568 | Gittard et al. | Nov 2021 | A1 |
20210379302 | Sigmon et al. | Dec 2021 | A1 |
20220040006 | Surti et al. | Feb 2022 | A1 |
20230016512 | Slattery et al. | Jan 2023 | A1 |
20230390540 | Pic et al. | Dec 2023 | A1 |
Number | Date | Country |
---|---|---|
9382598 | Mar 1999 | AU |
2009244462 | Nov 2009 | AU |
2009330505 | Jun 2011 | AU |
2011202035 | Nov 2011 | AU |
2010253997 | Dec 2011 | AU |
2014237970 | Sep 2015 | AU |
2014329827 | Apr 2016 | AU |
112022023464.3 | Dec 2022 | BR |
2194096 | Aug 2005 | CA |
2723183 | Nov 2009 | CA |
2747390 | Jul 2010 | CA |
2751538 | Aug 2010 | CA |
2763135 | Dec 2010 | CA |
2585845 | Dec 2012 | CA |
2925900 | Apr 2015 | CA |
2737832 | Feb 2016 | CA |
15244 | Sep 1897 | CH |
257250 | Mar 1949 | CH |
101068555 | Nov 2007 | CN |
101820935 | Sep 2010 | CN |
105050630 | Nov 2015 | CN |
105792869 | Jul 2016 | CN |
201621061301.6 | Sep 2016 | CN |
201820339550.X | Mar 2018 | CN |
110691615 | Jan 2020 | CN |
112546336 | Mar 2021 | CN |
113080819 | Jul 2021 | CN |
114514017 | May 2022 | CN |
115697176 | Feb 2023 | CN |
3024749 | Feb 1982 | DE |
3108918 | Sep 1982 | DE |
3613762 | Nov 1987 | DE |
69529495 | Mar 2003 | DE |
69530843 | Jun 2003 | DE |
10 2004 011 444 | Sep 2005 | DE |
60210063 | May 2006 | DE |
602005005081 | Apr 2008 | DE |
102010019222 | Nov 2013 | DE |
308269 | Mar 1989 | EP |
0 692 273 | Jan 1996 | EP |
0738498 | Oct 1996 | EP |
0690732 | Jan 2003 | EP |
0767624 | May 2003 | EP |
1293559 | Jul 2005 | EP |
1550713 | Jul 2005 | EP |
1365824 | Mar 2006 | EP |
1804926 | Feb 2008 | EP |
2277577 | Jan 2011 | EP |
2384871 | Nov 2011 | EP |
2391411 | Dec 2011 | EP |
2435114 | Apr 2012 | EP |
2680912 | Aug 2015 | EP |
2934629 | Oct 2015 | EP |
2968651 | Jan 2016 | EP |
3150240 | May 2017 | EP |
2375960 | Oct 2018 | EP |
3052168 | Nov 2019 | EP |
3190981 | Nov 2019 | EP |
3615094 | Mar 2020 | EP |
4041196 | Aug 2022 | EP |
4161346 | Apr 2023 | EP |
2863503 | Dec 2003 | FR |
2877240 | Jan 2007 | FR |
10563 | Dec 1896 | GB |
1254534 | Nov 1971 | GB |
2300371 | Nov 1996 | GB |
0100756 | Mar 2001 | GB |
S4838435 | May 1973 | JP |
S5667464 | Jun 1981 | JP |
4022109 | Apr 1992 | JP |
5-192404 | Aug 1993 | JP |
H08206229 | Aug 1996 | JP |
1997-253032 | Sep 1997 | JP |
10505253 | May 1998 | JP |
10-508790 | Sep 1998 | JP |
2001-520918 | Nov 2001 | JP |
2002-028224 | Jan 2002 | JP |
2003024833 | Jan 2003 | JP |
2003-126026 | May 2003 | JP |
2004521677 | Jul 2004 | JP |
2004-535246 | Nov 2004 | JP |
2005270372 | Jun 2005 | JP |
3719608 | Nov 2005 | JP |
2007-529280 | Oct 2007 | JP |
2009-530051 | Aug 2009 | JP |
2011508588 | Mar 2011 | JP |
2011-519679 | Jul 2011 | JP |
2011235962 | Nov 2011 | JP |
2012-513284 | Jun 2012 | JP |
2012-527974 | Nov 2012 | JP |
5502801 | May 2014 | JP |
5631332 | Nov 2014 | JP |
5670439 | Dec 2014 | JP |
2016512069 | Apr 2016 | JP |
6047546 | Nov 2016 | JP |
6552115 | Jul 2019 | JP |
2020517399 | Jun 2020 | JP |
6715274 | Jul 2020 | JP |
6807742 | Dec 2020 | JP |
2020 023110 | Feb 2022 | JP |
2022521497 | Apr 2022 | JP |
2022551509 | Sep 2022 | JP |
102387327 | Apr 2022 | KR |
10-2023-0002873 | May 2023 | KR |
978999 | Dec 1982 | SU |
1719844 | Feb 2021 | TW |
WO 198203545 | Oct 1982 | WO |
WO2008023545 | Oct 1982 | WO |
WO1985002346 | Jun 1985 | WO |
WO1992020312 | Nov 1992 | WO |
WO1994028798 | Dec 1994 | WO |
WO 199519799 | Jul 1995 | WO |
WO 1996009085 | Mar 1996 | WO |
WO 1996025190 | Aug 1996 | WO |
WO 199600524 | Nov 1996 | WO |
WO1996037245 | Nov 1996 | WO |
WO1996040327 | Dec 1996 | WO |
WO1997020585 | Jun 1997 | WO |
WO 199912595 | Mar 1999 | WO |
WO 199921599 | May 1999 | WO |
WO 02055139 | Jul 2002 | WO |
WO2002053014 | Jul 2002 | WO |
WO 2003007797 | Jan 2003 | WO |
WO2004002551 | Jan 2004 | WO |
WO2004073863 | Sep 2004 | WO |
WO2005089472 | Sep 2005 | WO |
WO2005100980 | Oct 2005 | WO |
WO 2006048536 | May 2006 | WO |
WO 20006090149 | Aug 2006 | WO |
WO 2007112185 | Oct 2007 | WO |
WO2008008845 | Jan 2008 | WO |
WO 2009088576 | Jul 2009 | WO |
WO2009091549 | Jul 2009 | WO |
WO 2009137438 | Nov 2009 | WO |
WO 2010074949 | Jul 2010 | WO |
WO 2010088146 | Aug 2010 | WO |
WO 2010138703 | Dec 2010 | WO |
WO 2012118466 | Sep 2012 | WO |
WO2013093798 | Jun 2013 | WO |
WO 2014099662 | Jun 2014 | WO |
WO 2014149617 | Sep 2014 | WO |
WO2015050814 | Apr 2015 | WO |
WO 2016038593 | Mar 2016 | WO |
WO 2016111373 | Jul 2016 | WO |
WO 2017006684 | Jan 2017 | WO |
WO 2017028701 | Feb 2017 | WO |
WO 2018200695 | Jan 2018 | WO |
WO 2020254447 | Dec 2020 | WO |
WO 2021071751 | Apr 2021 | WO |
WO 2021141791 | Jul 2021 | WO |
WO 2021247850 | Dec 2021 | WO |
WO 2023287654 | Jan 2023 | WO |
WO 2023076076 | May 2023 | WO |
Entry |
---|
Hemospray Endoscopic Hemostat Brochure, Cook, Jun. 2018 ESC-D43196-EN-F. |
Communication and Written Opinion dated Jan. 13, 2023 in European Application No. 21736099.9 (14 pages). |
International Search Report and Written Opinion of the International Searching Authority dated Dec. 3, 2021 in International Application No. PCT/US2021/035682 (22 pages). |
First Office Action and English Translation in Chinese Application No. 2018800357848, dated Jun. 9, 2021 (9 pages). |
Response to First Office Action in Chinese Application No. 2018800357848, dated Sep. 17, 2021 (12 pages). |
Second Office Action and English Translation in Chinese Application No. 2018800357848, dated Dec. 1, 2021 (8 pages). |
Response to Second Office Action in Chinese Application No. 2018800357848, dated March 29, 2022 (9 pages). |
Third Office Action and English Translation in Chinese Application No. 2018800357848, dated Mar. 29, 2022 (9 pages). |
Response to Examination Report in European Application No. 18724076.7, dated Feb. 25, 2022 (12 pages). |
Written Submissions in European Application No. 14789657.5 filed Jan. 7, 2022 (51 pages). |
Opponent's Written Submissions in European Application No. 14789657.5 filed Jan. 18, 2022 (25 pages). |
First Office Action in Chinese Patent Application No. 2020111614040 dated Mar. 21, 2022 (15 pages). |
Cardinal IP Services, “Prevention of Spray Activation During System Closure” (DN-9175) Patentability Search of Disclosure, 13 pages, dated Sep. 30, 2020. |
Cardinal IP Services, “Water Ingress Prevention Via Positive (Active/Passive) Air Flow” (DN-9171 and DN-9184) Patentability Search of Disclosure, 15 pages, dated Jan. 13, 2021. |
Cardinal IP Services, “Preventing Accidental Powder Deployment” (DN-9387) Patentability Search of Disclosure, 9 pages, dated Nov. 9, 2021. |
Cardinal IP Services, “Positive Pressure Delivery Mechanism for a Therapeutic Agent Delivery Device” (DN-9347) Patentability Search of Disclosure, 13 pages, dated Oct. 12, 2021. |
Cardinal IP Services, “Catheter Distal End Features to Prevent Lens Irrigation Fluid Ingress” (DN-9378) Patentability Search of Disclosure, 16 pages, dated Nov. 5, 2021. |
Cardinal IP Services, “Device That Allows For Cleaning of Catheter and Camera Lens on Endoscope Distal Tip” (DN-9495) Patentability Search of Disclosure, 11 pages, dated Jan. 3, 2022. |
PCT International Search Report in related Application No. PCT/US2022/036498 dated Oct. 27, 2022 (15 pages). |
Cook Hemospray Set-Up Video. Describes Turning of Valve to Allow for Trigger to Function; Retrieved from https://www.cookmedical.com/products/35a4a7f2-867b-4081-a933-44ea06277852/, dated 2020. |
Patentability Search: “Review of Cook's Hemostatic and Mucoadhesive Patents” dated Feb. 14, 2023 (32 pages). |
Patentability Search of Disclosure Entitled “Device That Reduces Fluid Ingress in the Catheter” (DN-9596) Prepared by Cardinal IP Services, dated Aug. 24, 2022 (12 pages). |
Invitation to Pay Additional Fee and, Where Applicable, Protest Fee in PCT Application Serial No. PCT/US2022/047013, dated Feb. 6, 2023 (13 pages). |
International Preliminary Report on Patentability in PCT Application No. PCT/US/2021/035682, dated Dec. 6, 2022 (13 pages). |
International Search Report and The Written Opinion of the International Searching Authority in PCT Application Serial No. PCT/US2022/047013, dated Mar. 27, 2023 (20 pages). |
Office Action dated Aug. 4, 2010 for U.S. Appl. No. 12/435,574, 7 pgs. |
Response to Office Action for U.S. Appl. No. 12/435,574, filed Nov. 3, 2010, 10 pgs. |
Office Action dated Feb. 17, 2011 for U.S. Appl. No. 12/435,574, 8 pgs. |
Response to Office Action for U.S. Appl. No. 12/435,574, filed May 13, 2011, 11 pgs. |
Office Action dated Aug. 22, 2011 for U.S. Appl. No. 12/435,574, 9 pgs. |
Response to Office Action for U.S. Appl. No. 12/435,574 filed Nov. 22, 2011, 10 pgs. |
Office Action dated Mar. 30, 2012 for U.S. Appl. No. 12/435,574, 9 pgs. |
Response to Office Action for U.S. Appl. No. 12/435,574 filed Aug. 30, 2012, 11 pgs. |
Restriction Requirement dated May 25, 2012 for U.S. Appl. No. 12/633,027, 7 pgs. |
Response to Restriction Requirement filed Jul. 2, 2012 for U.S. Appl. No. 12/633,027, 7 pgs. |
Office Action dated Apr. 14, 2011 for U.S. Appl. No. 12/787,796, 9 pgs. |
Response to Office Action filed Jul. 14, 2011 for U.S. Appl. No. 12/787,796, 11 pgs. |
Notice of Allowance dated Oct. 18, 2011 for U.S. Appl. No. 12/787,796, 10 pgs. |
International Search Report and Written Opinion for PCT/US2009/067076, mailed Apr. 14, 2010, 23 pgs. |
International Search Report and Written Opinion for PCT/US2010/036381, mailed Aug. 20, 2010, 16 pgs. |
International Preliminary Report on Patentability for PCT/US2009/042781, mailed Nov. 18, 2010, 10 pgs. |
International Search Report completed Sep. 22, 2009 for PCT/US2009/042781, 7 pgs. |
Alto Shooter Catalog, Kaigen, English and Japanese, Jun. 1994, 8 pgs. |
Decker, “An Efficient Method For The Application Of Avitene Hemostatic Agent”, Surgeg, Gynecology & Obstetrics, 1991, vol. 172, No. 6, 2 pgs. |
Endo-Avitene™ Brochure “Microfibrillar Collagen Hemostat in an Endoscopic Delivery System”, from MedChem Products, 4 pgs, 1992. |
Fagelman, et al. “A Simple Method For Application Of Microfibrilar Colagen”, Surgery, Gynecology & Obstetrics, Jun. 1980, vol. 150, No. 6, 3 pgs. |
Hoshino, et al. “Trans-endoscopic Drug Propulsion Therapy”, Diagnostic Endoscopy, 1993, vol. 5, 6 pgs. |
Surgical Armamentarium, Copyright 1973 V. Mueller, 3 pgs. |
Hoshino, “Transendoscopic Projectile Drug Delivery”, Gastroenterologia Japonica, vol. 25, No. 5, Jun. 15, 1990, 1 page. |
Park et al., “A randomized comparison of a new flexible bipolar hemostasis forceps designed principally for NOTES versus a conventional surgical laparoscopic bipolar forceps for intra-abdominal vessel sealing in a porcine model”, Gastrointestinal Endoscopy 2010, vol. 71, No. 4, pp. 835-841. |
Fritscher-Ravens et al., “Beyond NOTES: randomized controlled study of different methods of flexible endoscopic hemostasis of artifically induced hemorrhage, via NOTES access to the Beritoneal cavity”, Endoscopy 2009, vol. 41, pp. 29-35. |
Final Office Action for U.S. Appl. No. 12/435,574 mailed Feb. 17, 2011, 8 pgs. |
Examiner Interview Summary for U.S. Appl. No. 12/435,574 dated Jun. 10, 2011, 3 pgs. |
Notice of Appeal for U.S. Appl. No. 12/435,574 filed Aug. 17, 2011, 1 pg. |
Notice of Allowance dated Oct. 5, 2012 for U.S. Appl. No. 12/633,027, 9 pgs. |
International Preliminary Report on Patentability for PCT/US2009/067076 issued Jun. 29, 2011, 12 pgs. |
International Preliminary Report on Patentability for PCT/US2010/036381 issued Nov. 29, 2011, 7 pgs. |
Examination Report for Australian Patent Application No. 2009244462 issued Sep. 27, 2012; 4 pgs. |
Response to Examination Report for Australian Patent Application No. 2009244462 filed Feb. 19, 2013; 8 pgs. |
Examination Report for Canadian Patent Application No. 2,723,183 issued Aug. 17, 2012, 2 pgs. |
Response to Examination Report for Canadian Patent Application No. 2,723,183 filed Feb. 11, 2013, 5 pgs. |
Examination Report for European Patent Application No. 09743424.5 issued Nov. 14, 2011, 5 pgs. |
Response to Examination Report for European Patent Application No. 09743424.5 filed Mar. 14, 2012, 10 pgs. |
Examination Report for European Patent Application No. 09743424.5 issued Sep. 5, 2012, 6 pgs. |
Response to Examination Report for European Patent Application No. 09743424.5 filed Feb. 22, 2013, 4 pgs. |
Office Action for U.S. Appl. No. 13/351,524 issued Oct. 18, 2012, 14 pgs. |
Examiner Interview Summary for U.S. Appl. No. 13/351,524 issued Feb. 8, 2013, 4 pgs. |
Response to Office Action for U.S. Appl. No. 13/351,524 filed Feb. 12, 2013, 9 pgs. |
First Australian Examination Report for related AU Application No. 2014329827, dated Aug. 29, 2016, 4 pgs. |
Reply to First Australian Examination Report for related AU Application No. 2014329827, dated Nov. 10, 2016, 16 pgs. |
Notice of Acceptance For Patent Application for related AU Application No. 2014329827, dated Dec. 12, 2016, 3 pgs. |
Canadian Examination Report for related CA Application No. 2,925,900, dated Feb. 23, 2017, 4 pgs. |
European Communication Pursuant to Rule 161 (1) and 162 for related EP Application No. 14789657.5, dated May 11, 2016, 2 pgs. |
Reply To European Communication Report dated Nov. 10, 2016, 8 pgs. |
PCT International Search Report and Written Opinion for related Application No. PCT/US2014/058016, dated Apr. 21, 2015, 15 pgs. |
Office Action for JP2016-520011 dated May 2, 2017, 7 pgs. Including English translation. |
John Chadwick, Particle Size Control in Aerosol Packages, Dec. 2004, Aerosol Technical Solutions, pp. 1-3. |
Response to Examiner's Report in Canadian Application No. 2,925,900, dated Aug. 23, 2017, 6 pages. |
Notice of Allowance in Canadian Application No. 2,925,900, dated Dec. 1, 2017, 1 page. |
Office Action/Notification of Reason for Rejection in Japanese Application No. 2016-520011 dated Apr. 24, 2018, including English translation, 7 pages. |
Office Action in Chinese Application No. 201480065570.7 dated Jun. 22, 2018, including English translation, 21 pages. |
Response to Office Action for Chinese Application No. 201480065570.7 filed Oct. 5, 2018, including English translation, 6 pgs. |
Response to Office Action for Canadian Application No. 2,925,900 filed Aug. 23, 2017, 32 pgs. |
Response to Office Action for Japanese Application No. 2016-520011 filed Nov. 1, 2017, 11 pgs. |
Response to Office Action for Japanese Application No. 2016-520011 filed Oct. 23, 2018, 3 pgs. |
Office Action for EP 13818576.4 issued Oct. 9, 2018, 6 pgs. |
Second Office Action for CN201480065570.7 dated Mar. 11, 2019, 7 pages. |
Office Action for Japanese Patent Application 2016-520011 dated Apr. 2, 2019, 5 pgs. including English translation. |
Response to Office Action for Japanese Patent Application 2014-80065570.7 filed May 22, 2019, 11 pgs. |
Intent to Grant for European Application 14 789 657.5 dated Jun. 17, 2019, 35 pgs. |
Third Office Action for Chinese Patent Application No. 201480065570.7 dated Sep. 25, 2019, 14 pgs. including English translation. |
Office Action for Japanese Patent Application Serial No. 2016-520011 (Appeal No. 2019-0102252), dated Jun. 24, 2020, 8 pgs; including English translation. |
Office Action for Chinese Patent Application filing No. 201480065570.7 dated Apr. 3, 2020, 7 pgs. including English translation. |
Notice of Opposition for European Patent Application No. 14789657.5 dated Aug. 26, 2020, 28 pgs. |
ASTM, “ASTM E2651-10, Standard Guide for Powder Particle Size Analysis”, West Conshohocken, PA, USA: ASTM International, 2010. |
Muzzio , F.J. et al., “Sampling and characterization of pharmaceutical powders and granular blends”, International Journal of Pharmaceutics , vol. 250, No. 51-64, 2003. |
Kuchling, H., “Taschenbuch der Physik”, Fachbuchverlag Leipzig GmbH, 1995, Ed. 15: pp. 166-169; 9 pages including English translation. |
Kibbe , A.H. et al., “Lactose. In: R.C. Rowe et al. (eds). Handbook of Pharmaceutical Excipients”, London: Pharmaceutical Press, 2003: pp. 323-332. |
National Geographic Area Coordination Center, “‘Weed Washer’ What is a Micron? (Micron v/s Mesh). Reference: Mesh Micron Conversion Chart”, [cited Jun. 8, 2020] Available from: [https://gacc.nifc.gov/nrcc/dispatch/equipment_supplies/agree-contract/forms/M icronMesh.pdf]. |
Mortazavi, S.M.J., “Development of a Novel Mineral Based Haemostatic Agent Consisting of a Combination of Bentonite and Zeolite Minerals”, J Ayub Med Coll Abbottabad , vol. 21(1), 2009. |
ChemicalBook Inc., “Chemical Book, CAS DataBase List, Bentonite”, CAS No. 1302-78-9 II , [cited Jun. 8, 2020] Available from: [https://www.chemicalbook.com/CASEN_1302-78-9.htm]. |
Kesavan, J. et al., “Density Measurements of Materials used in Aerosol Studies”, Edgewood, 2000. |
Arefnia, A. et al., “Comparative Study on the Effect of Tire-Derived Aggregate on Specific Gravity of Kaolin”, Electronic Journal of Geotechnical Engineering , vol. 18(B), Jan. 2013: pp. 335-344. |
Wikipedia, “Wikipedia. Amoxicillin”, [cited Jun. 8, 2020] Available from: [https://en.wikipedia.org/wiki/Amoxicillin]. |
ChemicalBook Inc., “Chemical Book. Norfloxacin”, [cited Jun. 8, 2020] Available from: [https://www.chemicalbook.com/Chemical ProductProperty_US_CB1711035.aspx]. |
Wong Kee Song , L.-M. et al., “Emerging technologies for endoscopic hemostasis”, Gastrointest. Endosc., vol. 75(5), May 2012: pp. 933-937. |
Bridevaux, et al. “Short-term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax; a prospective European multicentre study” Eur Respir J 2011; 38: 770-773. (Year: 2011). |
International Preliminary Report on Patentability in PCT Application No. PCT/US/2014/058016, dated Oct. 2, 2013 (12 pages). |
Reexamination Request in Chinese Application No. 201480065570.7, dated Jul. 3, 2020 (10 pages). |
Notice of Allowance in Chinese Application No. 201480065570.7, dated Aug. 12, 2020 (4 pages). |
Response to Office Action in European Application No. 14789657.5, dated Mar. 22, 2021 (85 Pages). |
Response to Office Action in Japanese Application No. 2016-520011, dated Sep. 15, 2020 (4 pages). |
Decision on Appeal in Japanese Application No. 2016-520011, dated Nov. 10, 2020 (4 pages). |
Summons to Attend Oral Proceedings in European Application No. 14789657.5, dated Aug. 26, 2021 (13 pages). |
PCT Invitation to Pay Additional Fees in related Application No. PCT/US2021/035682 dated Oct. 12, 2021 (16 pages). |
Partial European Search Report in EP Application No. 23214435.2, dated Apr. 23, 2024 (14 pages). |
Medgadget, Convesaid, A Hemostat Powder Spray That Can't Cause Embolisms, (Team Consulting) Mar. 16, 2018 (4 pages). |
Partial European Search Report in EP Application No. 23204400.8, dated Mar. 18, 2024 (17 pages). |
International Preliminary Report on Patentability and Written Opinion regarding PCT/US2022/036498 dated Jan. 25, 2024, 9 pages. |
Office Action in Japanese Patent Application No. 2022-570158, dated Nov. 17, 2023 (9 pages). |
Machine Translation of JP 1997-253032 (21 pages). |
International Preliminary Report on Patentability in PCT Application No. PCT/US2022/047013, dated Apr. 30, 2024 (12 pages). |
Japanese Decision of Refusal and English translation of the Office Action regarding 2022-570158 dated Jul. 23, 2024, 5 pages. |
Office Action for Japanese Patent Application No. 2011-508588 dated Mar. 25, 2014, 6 pages including English translation. |
Office Action dated Jun. 12, 2013 for Japanese Patent Application No. 2011-508588, 6 pages inlcluding English translation. |
Response to Office Action dated Oct. 10, 2013 for Japanese Patent Application No. 2011-508588, 3 pages. |
Examination Report from European Patent Office dated Nov. 28, 2013 for European Patent Application No. 09743424.5, 6 pgs. |
Examiner's Report dated Aug. 17, 2012 for Canadian Patent Application No. 2723183, 2 pgs. |
Response to Examiner's Report dated Feb. 11, 2013 for Canadian Patent Application No. 2723183, 5 pgs. |
Notice of Allowance dated Jul. 31, 2013 for Canadian Patent Application No. 2723183, 1 pg. |
Notice of Acceptance dated Apr. 2, 2013 for Australian Patent Application No. 2009244462, 3 pgs. |
Certificate of Grant dated Jul. 25, 2013 for Australian Patent Application No. 2009244462, 1 pg. |
Office Action dated Oct. 2, 2014 for U.S. Appl. No. 12/435,574, 10 pgs. |
Response to Office Action filed Feb. 24, 2015 for U.S. Appl. No. 12/435,574, 18 pgs. |
Office Action dated Jun. 12, 2015 for U.S. Appl. No. 12/435,574, 10 pgs. |
Response to Office Action filed Oct. 6, 2015 for U.S. Appl. No. 12/435,574, 19 pgs. |
Office Action dated dated Jun. 1, 2016 for U.S. Appl. No. 12/435,574, 13 pgs. |
Response to Office Action filed Aug. 2, 2016 for U.S. Appl. No. 12/435,574, 13 pgs. |
Office Action dated Nov. 15, 2016 for U.S. Appl. No. 12/435,574, 15 pgs. |
Notice of Allowance dated Aug. 10, 2017 for U.S. Appl. No. 12/435,572, 9 pgs. |
PCT International Search Report and Written Opinion for PCT/US2010/036381, mailed Aug. 20, 2010 (16 pages). |
Final Rejection for U.S. Appl. No. 13/351,524 issued Jun. 14, 2013, 12 pgs. |
RCE and Amendment for U.S. Appl. No. 13/351,524, filed Dec. 13, 2013, 10 pgs. |
Notice of Allowance for U.S. Appl. No. 13/351,524 issued Jan. 17, 2014, 9 pgs. |
Examination Report No. 1 for Australian Patent Application 2010253997 issued Mar. 15, 2013, 3 pgs. |
Examiner's Report for Canadian Patent Application 2,763,135 issued May 27, 2013, 3 pgs. |
Response to Examiner's Report for Canadian Patent Application 2,763,135 filed Nov. 27, 2013, 8 pgs. |
Communication for European Patent Application 10722265.5 dated Jan. 27, 2012, 2 pgs. |
Reply to Communication for European Patent Application 10722265.5 filed Jul. 27, 2012, 18 pgs. |
International Search Report and Written Opinion for PCT/US2013/075005 dated May 2, 2014, 13 pgs. |
Office Action dated Oct. 7, 2013 for U.S. Appl. No. 13/725,206, 8 pgs. |
Response to Office Action filed Feb. 6, 2014 for U.S. Appl. No. 13/725,206, 8 pgs. |
Office Action dated May 29, 2014 for U.S. Appl. No. 13/725,206, 10 pgs. |
Pre-Appeal Brief Request for Review filed Oct. 28, 2014 for U.S. Appl. No. 13/725,206, 7 pgs. |
Notice of Panel Decision dated Nov. 25, 2014 for U.S. Appl. No. 13/725,206, 2 pgs. |
Amendment and Response After Final filed Jan. 26, 2015 for U.S. Appl. No. 13/725,206, 9 pgs. |
Advisory Action dated Feb. 13, 2015 for U.S. Appl. No. 13/725,206, 3 pgs. |
Amendment and Response After Final filed Mar. 30, 2015 for U.S. Appl. No. 13/725,206, 8 pgs. |
Notice of Allowance dated Apr. 9, 2015 for U.S. Appl. No. 13/725,206, 8 pgs. |
Communication Pursuant to Rules 161(1) and 162 EPC for EPO13818576.4 dated Aug. 12, 2015, 2 pgs. |
Notification of Reason for Rejection for JP2014-254907 dated Feb. 9, 2016, 6 pgs including English translation. |
Office Action in European U.S. Appl. No. 22/802,397 dated Jun. 5, 2024 (23 pages). |
Final Office Action in U.S. Appl. No. 17/227,635 dated Aug. 30, 2024 (39 pages). |
Final Office Action in U.S. Appl. No. 18/143,844 dated Sep. 4, 2024 (68 pages). |
Extended European Search Report in European Application No. 23214435.2, dated Aug. 5, 2024 (14 pages). |
Notice of Allowance in U.S. Appl. No. 17/338,198, dated Sep. 9, 2024 (10 pages). |
Number | Date | Country | |
---|---|---|---|
20210379302 A1 | Dec 2021 | US |
Number | Date | Country | |
---|---|---|---|
63035270 | Jun 2020 | US |